Clarity Medical Systems, Inc.
Roundtable comes after the recent Russian Federation purchase of 42 RetCam Systems
Pleasanton, CA March 27, 2012 – Clarity Medical Systems, Inc. proudly announces the invitation of two company officers, Executive Vice President Mike Napier and Chief Medical Officer Barry J. Linder, MD, to participate in a roundtable discussion on Retinopathy of Prematurity (ROP) being held by the Russian Ministry of Healthcare and Social Development on March 29, 2012.
The conference, intended to further the understanding of ROP and available treatment methods in the Russian medical community, will be attended by a range of specialists including Pediatric Ophthalmologists and Neonatologists. Mr. Napier will speak on the organization of ROP treatment and the history of digital imaging of newborns in the United States, while Dr. Linder will speak on the use of RetCam – Clarity’s flagship product for the imaging and management of ROP – around the world, with a focus on China.
“The timing of this conference is on the heels of the recent purchase of 42 RetCam Systems by the Russian Federation and provides us with an excellent opportunity to share our ROP expertise with their thought leaders” commented Mr. Napier.
Dr. Linder added, “We’re incredibly excited to be included in this discussion of contemporary ROP treatment methods with the Russian medical community. Russia is in the middle of taking important steps to identify and combat ROP, and Clarity is honored to be a part of that process.”
About ROP
Retinopathy of prematurity (ROP) is a leading cause of blindness in children in developed countries around the world and an increasing cause of blindness in developing countries. The retina lines the inside of the eye, acting as a film and initiating the electrical and chemical responses responsible for triggering nerve impulses. When an infant is born prematurely, the vascular network tasked with nourishing the retina has not fully developed. Consequently, in some infants, abnormal vessels develop: this condition is known as ROP. Abnormal vessel growth, if left untreated, can lead to retinal detachment and blindness.
About Clarity Medical Systems, Inc.
Clarity Medical Systems, Inc. develops, manufactures and markets advanced pediatric ophthalmic imaging systems, guidance and informatics tools that enhance the clinician’s ability to diagnose, manage, and treat eye disorders. The company's RetCam product line is helping to improve the quality of eye healthcare in pediatric populations worldwide and is sold to leading Neonatal Intensive Care Units on a global basis. To date, over 1,100 RetCam systems have been installed and the eyes of more than a million children have been imaged in over 85 countries.
US Contact: Cassandra Dump
Phone: 619.971.1887
[email protected]